Oncology Clinical Trials in Salt Lake City, UT

As of June 2026, 226 paid clinical trials are recruiting for Oncology in Salt Lake City, Utah. Oncology trials evaluate immunotherapies, targeted therapies, antibody-drug conjugates, and combination regimens across solid tumors and blood cancers — from early-phase first-in-human studies to phase 3 registration trials. Compensation typically covers time, travel, and study visits, and many studies also include study-related medical care at no cost.

Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: June 12, 2026.

Filter results

Filter results

State

City

Facility

Phase

Study type

Intervention

Recruitment status

Condition

Sex

Age

Healthy volunteers only

226 clinical trials for Oncology

·Clear filters·↓ Download CSV

A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation

for Prostate Cancer

Drug: Saruparib

42 locations incl. Phoenix

Sponsor: AstraZeneca

Sex: Male·Age: 18+

Code: NCT06952803·Phase 3·Recruiting

Apply to this trial

A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

for Breast Cancer

102 locations incl. Chandler

Sponsor: Pfizer

Sex: All·Age: 18+

Code: NCT07062965·Phase 3·Recruiting

Apply to this trial

A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors

for Pancreatic Ductal Adenocarcinoma

13 locations incl. Los Angeles

Sponsor: Verastem, Inc.

Sex: All·Age: 18+

Code: NCT07020221·Phase 1, Phase 2·Recruiting

Apply to this trial

Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)

for Myelodysplastic Syndrome

138 locations incl. Berkeley

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT06577441·Phase 2·Recruiting

Apply to this trial

High-dose Prophylactic Gabapentin (HOPE) vs. Placebo to Prevent Opioid Use for Oral Mucositis Pain During Concurrent Chemoradiation for Head and Neck Cancer

for Head and Neck Squamous Cell Carcinoma

200 locations incl. Gilbert

Sponsor: Alliance for Clinical Trials in Oncology

Sex: All·Age: 18+

Code: NCT06992427·Phase 3·Recruiting

Apply to this trial

Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients

for PDAC

18 locations incl. Scottsdale

Sponsor: Tango Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT06922591·Phase 1, Phase 2·Recruiting

Apply to this trial

JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration

for Advanced Solid Tumors

4 locations incl. Rochester

Sponsor: Jacobio Pharmaceuticals Co., Ltd.

Sex: All·Age: 18+

Code: NCT06973564·Phase 1, Phase 2·Recruiting

Apply to this trial

Impact of Multimodal Telerehabilitation in Rural Patients With Metastatic Prostate Cancer

for Prostate Cancer

1 location in Salt Lake City

Sponsor: University of Utah

Sex: Male·Age: 21+

Code: NCT07032584·Recruiting

Apply to this trial

A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)

for Malignant Neoplasm

17 locations incl. Los Angeles

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 1 Month - 17

Code: NCT06941272·Phase 1, Phase 2·Recruiting

Apply to this trial

5 vs. 9-day Course of Whole Breast Radiotherapy With Boost for Early-stage Breast Cancer

for Breast Cancer

1 location in Salt Lake City

Sponsor: University of Utah

Sex: Female·Age: 18+

Code: NCT06961955·Phase 2·Recruiting

Apply to this trial

Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)

for Acute Myeloid Leukemia

129 locations incl. Tucson

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT06672146·Phase 2·Recruiting

Apply to this trial

Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

for NSCLC (Non-small Cell Lung Cancer)

Drug: daraxonrasib

39 locations incl. Birmingham

Sponsor: Revolution Medicines, Inc.

Sex: All·Age: 18+

Code: NCT06881784·Phase 3·Recruiting

Apply to this trial

Testing the Combination of Two Approved Drugs and One Experimental Drug in Patients With Relapsed or Refractory Multiple Myeloma

for Recurrent Multiple Myeloma

40 locations incl. Ames

Sponsor: Alliance for Clinical Trials in Oncology

Sex: All·Age: 18+

Code: NCT06232044·Phase 1, Phase 2·Recruiting

Apply to this trial

The SENTRY Study: Testing Whether Changes in Platelet RNA Enhance the Early Diagnosis of Ovarian Cancer

for Ovarian Cancer

1 location in Salt Lake City

Sponsor: University of Utah

Sex: Female·Age: 21+·Accepts healthy volunteers

Code: NCT06665945·Recruiting

Apply to this trial

A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors

for Metastatic Solid Tumor

20 locations incl. Tucson

Sponsor: Coherus Oncology, Inc.

Sex: All·Age: 18+

Code: NCT06657144·Phase 1·Recruiting

Apply to this trial

BBO-11818 in Adult Subjects With KRAS Mutant Cancer

for Non-Small Cell Lung Cancer

16 locations incl. Los Angeles

Sponsor: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)

Sex: All·Age: 18+

Code: NCT06917079·Phase 1·Recruiting

Apply to this trial

Safety, Pharmacokinetics, and Efficacy of AI-081, a Bispecific Antibody for PD-1 And VEGF in Advanced Solid Tumors

for Advanced Solid Tumor

Drug: AI-081

19 locations incl. Birmingham

Sponsor: OncoC4, Inc.

Sex: All·Age: 18+

Code: NCT06635785·Phase 1, Phase 2·Recruiting

Apply to this trial

Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss

for Non Small Cell Lung Cancer

15 locations incl. Scottsdale

Sponsor: Tango Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT06810544·Phase 1, Phase 2·Recruiting

Apply to this trial

Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer

for Fallopian Tube Endometrioid Adenocarcinoma

Drug: Bevacizumab

658 locations incl. Birmingham

Sponsor: NRG Oncology

Sex: All·Age: 18+

Code: NCT06580314·Phase 3·Recruiting

Apply to this trial

Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial

for Anatomic Stage IV Breast Cancer AJCC v8

58 locations incl. Phoenix

Sponsor: NRG Oncology

Sex: All·Age: 18+

Code: NCT06500481·Phase 3·Recruiting

Apply to this trial

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

for Non-Small Cell Lung Cancer

Drug: Ivonescimab

89 locations incl. Chandler

Sponsor: Summit Therapeutics

Sex: All·Age: 18+

Code: NCT06767514·Phase 3·Recruiting

Apply to this trial

Pirtobrutinib in Combination With Rituximab in Adults With Untreated Marginal Zone Lymphoma (PIONEER-MZL)

for Marginal Zone Lymphoma

Drug: Rituximab

2 locations incl. St Louis

Sponsor: University of Utah

Sex: All·Age: 18+

Code: NCT06390956·Phase 2·Recruiting

Apply to this trial

Topical Tretinoin Prophylaxis for Anti-EGFR Induced Skin Toxicity in Patients With Solid Tumors

for Metastatic Solid Tumor

1 location in Salt Lake City

Sponsor: University of Utah

Sex: All·Age: 18+

Code: NCT06358677·Phase 2·Recruiting

Apply to this trial

Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma

for AIDS-Related Diffuse Large B-cell Lymphoma

6 locations incl. Duarte

Sponsor: AIDS Malignancy Consortium

Sex: All·Age: 18+

Code: NCT05077527·Phase 1·Recruiting

Apply to this trial

EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma

for Glioblastoma

32 locations incl. Phoenix

Sponsor: NovoCure GmbH

Sex: All·Age: 18+

Code: NCT06556563·Phase 3·Recruiting

Apply to this trial

A Phase 1 Study of LNCB74 in Advanced Solid Tumors

for Ovarian Cancer

14 locations incl. Newport Beach

Sponsor: NextCure, Inc.

Sex: All·Age: 18+

Code: NCT06774963·Phase 1·Recruiting

Apply to this trial

A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

for Carcinoma, Non-Small-Cell Lung

Drug: Amivantamab

150 locations incl. Daphne

Sponsor: Janssen Research & Development, LLC

Sex: All·Age: 18+

Code: NCT06667076·Phase 2·Recruiting

Apply to this trial

Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain

for Anatomic Stage IV Breast Cancer AJCC v8

256 locations incl. Tucson

Sponsor: NRG Oncology

Sex: All·Age: 18+

Code: NCT06500455·Phase 3·Recruiting

Apply to this trial

XL092 in Patients With Metastatic Castration-Resistant Prostate Cancer

for Metastatic Castration-resistant Prostate Cancer

1 location in Salt Lake City

Sponsor: University of Utah

Sex: Male·Age: 18+

Code: NCT06568562·Phase 2·Recruiting

Apply to this trial

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)

for Lung Non-Small Cell Carcinoma

248 locations incl. Jonesboro

Sponsor: SWOG Cancer Research Network

Sex: All·Age: 18+

Code: NCT06116682·Phase 2·Recruiting

Apply to this trial

Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors

for Neuroblastoma

20 locations incl. Birmingham

Sponsor: Milton S. Hershey Medical Center

Sex: All·Age: Up to 30

Code: NCT06541262·Phase 1, Phase 2·Recruiting

Apply to this trial

A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

for Non-small Cell Lung Cancer

Drug: Relatlimab

45 locations incl. Mobile

Sponsor: Bristol-Myers Squibb

Sex: All·Age: 18+

Code: NCT06561386·Phase 3·Recruiting

Apply to this trial

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

for Acute Myeloid Leukemia

Drug: Venetoclax

221 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT06317649·Phase 2·Recruiting

Apply to this trial

A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

for Breast Cancer

165 locations incl. Daphne

Sponsor: Stemline Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT06492616·Phase 3·Recruiting

Apply to this trial

Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

for Acute Myeloid Leukemia

211 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18 - 59

Code: NCT05554406·Phase 2·Recruiting

Apply to this trial

A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)

for Head and Neck Squamous Cell Carcinoma

Drug: Petosemtamab

37 locations incl. Mobile

Sponsor: Merus B.V.

Sex: All·Age: 18+

Code: NCT06525220·Phase 3·Recruiting

Apply to this trial

A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors

for Solid Tumor

19 locations incl. Little Rock

Sponsor: NiKang Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT06586957·Phase 1·Recruiting

Apply to this trial

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

for Acute Myeloid Leukemia

Drug: Venetoclax

167 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18 - 59

Code: NCT05554393·Phase 2·Recruiting

Apply to this trial

MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors

for Pancreatic Ductal Adenocarcinoma

25 locations incl. Duarte

Sponsor: Eli Lilly and Company

Sex: All·Age: 18+

Code: NCT06586515·Phase 1·Recruiting

Apply to this trial

A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)

for Melanoma

104 locations incl. Chandler

Sponsor: Regeneron Pharmaceuticals

Sex: All·Age: 18+

Code: NCT06246916·Phase 3·Recruiting

Apply to this trial

Conditions in Oncology (Salt Lake City, UT)

Solid tumor· 35 Non-small cell lung cancer (NSCLC)· 28 Breast cancer· 25 Multiple myeloma· 16 Acute myeloid leukemia (AML)· 16 Cancer (any)· 15 Non-Hodgkin lymphoma· 12 Pancreatic cancer· 11 Ovarian cancer· 11 Colorectal cancer· 10 Diffuse large B-cell lymphoma (DLBCL)· 10 Prostate cancer· 9 Endometrial cancer· 9 Head and neck cancer· 9 Glioblastoma· 8 Myelodysplastic syndromes (MDS)· 8 Hematologic malignancy· 8 Melanoma· 8 Metastatic breast cancer· 7 Metastatic prostate cancer· 7 Myelofibrosis· 7 Lung cancer· 6 Acute lymphoblastic leukemia· 6 Leukemia (other)· 6 Mantle cell lymphoma· 6 Neuroblastoma· 6 Gastric cancer· 5 Bladder cancer· 5 Chronic lymphocytic leukemia (CLL)· 5 Marginal zone lymphoma· 5 Neuroendocrine tumors· 5 Triple-negative breast cancer· 4 Esophageal cancer· 4 Gynecologic cancer· 4 Kidney cancer· 3 Cervical cancer· 3 Fallopian tube cancer· 3 Brain metastases· 3 Follicular lymphoma· 3 Small lymphocytic lymphoma· 3 HER2-negative breast cancer· 2 Gastroesophageal junction cancer· 2 Biliary tract cancer· 2 Glioma· 2 Myeloproliferative neoplasm· 2 Hodgkin lymphoma· 2 Skin cancer· 2 Osteosarcoma· 2 Ewing sarcoma· 2 HER2-positive breast cancer· 1 Small cell lung cancer· 1 Metastatic colorectal cancer· 1 Colon cancer· 1 Rectal cancer· 1 Gastrointestinal cancer· 1 Brain cancer· 1 Burkitt lymphoma· 1 Thyroid cancer· 1 Sarcoma· 1 Rhabdomyosarcoma· 1 Pediatric cancer· 1 Mesothelioma· 1